Heart failure (HF) management has evolved significantly in recent years due to technological advancements and novel research findings.
Emerging pharmacological interventions include novel beta-blockers, ARNI (Angiotensin Receptor-Neprilysin Inhibitors), and SGLT2 (Sodium-Glucose Co-Transporter-2) inhibitors, demonstrating improved survival and reduced hospitalization rates.
Device-based therapies such as cardiac resynchronization therapy (CRT) and implantable cardioverter defibrillators (ICDs) have shown significant potential in HF management.
Telemedicine has emerged as a promising tool for remote patient monitoring, reducing hospital readmissions and enhancing patient adherence to treatment plans.
These advancements underscore the need for healthcare professionals to stay abreast of contemporary updates in HF management, ensuring optimal patient outcomes. Continued research and technological innovation are vital for further improvements in this field.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation